4Moving Biotech announces the closing of a €12 ... - 4p-pharma.com
Feb 10, 2026 · This trajectory illustrates a strong long-term strategy led by 4P-Pharma and built on its proprietary drug regeneration model, addressing untreated serious diseases and implemented …
4P-Pharma welcomes Marina Vasiliou, Christian Bechon, and Alain …
Sep 10, 2024 · “4P-Pharma is a promising French biotech company that prioritizes patients’ needs. The company’s main objective is to contribute to healthcare innovation in France and Europe while …
First Patient Enrolled in the Phase 2a Clinical Trial, INFLAM MOTION
Jul 16, 2025 · We are delighted to share that 4Moving Biotech, a spin-off of 4P-Pharma, has enrolled the first patient in its Phase 2a clinical trial, INFLAM MOTION.
4P-Pharma will present 4P-004 at the 2nd Therapeutic Discoveries ...
Feb 19, 2020 · 4P-Pharma will present a poster on 4P-004 during the 2nd Therapeutic Discoveries, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
4P-Pharma at CPHI Frankfurt 2025
Oct 9, 2025 · We’re excited to announce that 4P-Pharma will be attending CPHI Frankfurt 2025 🇩🇪 Our Business Development team, Roselina Lam, Anne-Claire Gaudiez and our CMC expert, Frédéric …
HAPPY NEW YEAR 2026 - 4P Pharma
Jan 8, 2026 · From now on, it is our shared decisions, our standards of excellence, and our collective commitment that will make the difference. The entire 4P-Pharma team wishes you a wonderful year …
4P Pharma, Translating Science to Medicine for Patients
Established in 2014, 4P-Pharma is a clinical stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients …
4P-Pharma at BIO Europe Spring 2024
Feb 20, 2024 · 4P-Pharma at BIO Europe Spring 2024 We look forward to attending BIOEuropeSpring, which will take place on March 18-20, 2024, in Barcelona. Our Business Development team, …
4P-Pharma Announces Total Capital of €15 Million Successfully …
Apr 29, 2024 · With this funding, 4P-pharma’s shareholders renew their confidence in the company’s drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical …
4P-Pharma presents 4P-004 data at the ACR/ARP Annual Meeting in …
Nov 8, 2019 · A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” (#1973) will be presented